Bacterial Vaginosis: Do High Recurrence Rates Suggest Sexual Transmission?
Infectious Diseases Summary and Comment
Over half of women with bacterial vaginosis had recurrence within 12 months.
By Daniel J. Diekema, MD, MS
June 9, 2006
Covering:
Bradshaw CS et al., J Infect Dis 2006 Jun 1; 193:1478-86
Condoms Reduce HPV Acquisition in Heterosexual Women
General Medicine Summary and Comment
The more frequently condoms were used, the lower the risk for HPV infection.
By Abigail Zuger, MD
June 30, 2006
Covering:
Winer RL et al., N Engl J Med 2006 Jun 22; 354:2645-54
Incidence of Vulvar Carcinoma Increasing
General Medicine Summary and Comment
A clear association exists between HPV and in situ vulvar carcinoma; the association is less clear for invasive cancer.
By Robert W. Rebar, MD
June 13, 2006
Covering:
Judson PL et al., Obstet Gynecol 2006 May; 107:1018-22
Modeling the Survival Benefits of HIV Treatment in the U.S.
HIV/AIDS Clinical Care Summary and Comment
Free
HIV treatments saved about 3 million years of life from 1989 through 2003 — or about 13 years per treated person.
By Stefano M. Bertozzi, MD, PhD, and Sergio Bautista-Arredondo, MSc
July 11, 2006
Covering:
Walensky RP et al., J Infect Dis 2006 Jul 1; 194:11-9
Vermund SH., J Infect Dis 2006 Jul 1; 194:1-5
Condoms Protect Against HPV Infection in Young Women
In a well-designed prospective study, consistent condom use reduced the risk for cervical and vulvovaginal HPV infection.
By Carlos del Rio, MD
July 11, 2006
Covering:
Winer RL et al., N Engl J Med 2006 Jun 22; 354:2645-54
Steiner MJ and Cates W Jr., N Engl J Med 2006 Jun 22; 354:2642-3
Concurrent Treatment of HIV and TB
HIV/AIDS Clinical Care Summary and Comment
Free
New case-control results add to a growing body of evidence that supports aggressively treating both HIV and TB.
By G. Sonia Nagy, MD
May 31, 2006
Covering:
Breen RAM et al., J Infect Dis 2006 May 15; 193:1437-40
Large Household Survey May Not Provide Accurate HIV Information
Data indicating stable HIV seroprevalence rates over the last decade are probably flawed.
By Abigail Zuger, MD
May 31, 2006
Covering:
McQuillan GM et al., J Acquir Immune Defic Syndr 2006 Apr 15; 41:651-6
Blurred Vision in HIV-Infected Patients: Think Ocular Syphilis
Infectious Diseases Summary and Comment
Over a 13-month period in one clinic, ocular syphilis was diagnosed in three patients taking potent ART.
By Neil M. Ampel, MD
May 19, 2006
Covering:
Balba GP et al., Am J Med 2006 May; 119:448.e21-5
AIDS: The First 25 Years
Reflections on the first 25 years of the HIV/AIDS pandemic
By Gerald H. Friedland, MD
May 10, 2006
DHHS Treatment Guidelines Updated
HIV/AIDS Clinical Care Clinical Practice Guideline Watch
New HIV treatment guidelines include updates on genotypic resistance testing and treatment interruptions.
By Abigail Zuger, MD
May 10, 2006
Covering:
How Long Will Vaccines Against HPV Remain Effective?
General Medicine Summary and Comment
Free
A new study indicates that the answer is at least 4 years.
By Robert W. Rebar, MD
May 5, 2006
Covering:
Harper DM et al., Lancet 2006 Apr 15; 367:1247-55
Antiretroviral Therapy During Pregnancy: How Safe?
Infectious Diseases Summary and Comment
Combination therapy that includes a protease inhibitor may increase the risk for preterm delivery.
By Daniel J. Diekema, MD, MS
May 5, 2006
Covering:
Cotter AM et al., J Infect Dis 2006 May 1; 193:1195-201
Tuomala RE and Yawetz S., J Infect Dis 2006 May 1; 193:1191-4
As with Squamous Tumors, HPV Is Key in Cervical Adenocarcinoma Etiology
Women's Health Summary and Comment
HPV infection was associated with an 80-fold increase in risk for cervical adenocarcinoma.
By Andrew M. Kaunitz, MD
May 2, 2006
Covering:
Castellsagué X et al., J Natl Cancer Inst 2006 Mar 1; 98:303-15
Genital Herpes in Heterosexual Men
Women's Health Summary and Comment
Most heterosexual men with HSV-2 infection were unaware of their disease status.
By Anna Wald, MD, MPH
May 2, 2006
Covering:
Sizemore JM Jr et al., J Infect Dis 2006 Apr 1; 193:905-11
Spectinomycin Discontinued as Treatment for Gonorrhea
Ceftriaxone is the only remaining alternative treatment for quinolone-resistant gonorrhea in the U.S.
By Carlos del Rio, MD
April 26, 2006
Covering:
Centers for Disease Control and Prevention., MMWR Morb Mortal Wkly Rep 2006 Apr 7; 55:370
Skin Findings in HIV Disease
Dermatology Summary and Comment
Highly active antiretroviral treatment has lessened the prevalence of troubling cutaneous disease in patients with HIV.
By Jan V. Hirschmann, MD
April 25, 2006
Covering:
Zancanaro PC et al., J Am Acad Dermatol 2006 Apr; 54:581-8
Media Exposure and Early Sexual Intercourse
General Medicine Summary and Comment
Exposure to sexually explicit content increases risk for early sexual intercourse among teens.
By Howard Bauchner, MD
April 14, 2006
Covering:
Brown JD et al., Pediatrics 2006 Apr; 117:1018-27
Evolving Mortality Patterns in HIV-Infected Patients
A report from U.S. military clinics documents steadily improving clinical outcomes for HIV-infected individuals and a shift to non-AIDS–related conditions as the primary causes of death.
By Keith Henry, MD
April 12, 2006
Covering:
Crum NF et al., J Acquir Immune Defic Syndr 2006 Feb 1; 41:194-200
After M184V, Continue the 3TC
Patients with the M184V mutation who continued 3TC alone, instead of stopping all treatment, had virologic and clinical benefits, and no new resistance mutations were observed.
By Paul E. Sax, MD
April 12, 2006
Covering:
Castagna A et al., AIDS 2006 Apr 4; 20:795-803
The Cost-Effectiveness of Expanding Prevention Programs
Implementing comprehensive HIV prevention programs in low- and middle-income countries would yield long-term cost savings.
By Salim S. Abdool Karim, MD, PhD
April 12, 2006
Covering:
Stover J et al., Science 2006 Mar 10; 311:1474-6
HIV Prevalence Remains High Among MSM in California
Results from a statewide survey suggest that one in five MSM are HIV-infected.
By Carlos del Rio, MD
April 12, 2006
Covering:
Xia Q et al., J Acquir Immune Defic Syndr 2006 Feb 1; 41:238-45
The Return of All-Nuke Regimens?
HIV/AIDS Clinical Care Summary and Comment
Free
In a pilot study, quadruple-NRTI regimens were as potent and tolerable as standard efavirenz-based regimens.
By Charles B. Hicks, MD
March 29, 2006
Covering:
Moyle G et al., Antivir Ther 2006 Jan; 11:73-8
Assessing the Cost of HIV Care
Patients with severe immunodeficiency incur substantially higher annual healthcare costs than those with moderate immunodeficiency. Physician reimbursement accounts for only a tiny percentage of the cost of HIV care, regardless of patient status.
By Paul E. Sax, MD
March 29, 2006
Covering:
Chen RY et al., Clin Infect Dis 2006 Apr 1; 42:1003-10
Mayer KH and Chaguturu S., Clin Infect Dis 2006 Apr 1; 42:1011-3
HCV Coinfection and Immunologic Response to Antiretroviral Therapy
HCV coinfection may be associated with blunted CD4-cell reconstitution after initiation of potent combination antiretroviral therapy.
By Rajesh T. Gandhi, MD
March 29, 2006
Covering:
Braitstein P et al., J Infect Dis 2006 Jan 15; 193:259-68
Nevirapine Once-Daily vs. Twice-Daily
Once-daily nevirapine yields the same daily drug exposure as twice-daily nevirapine, but leads to a lower Cmin and a higher Cmax .
By Shahin Lockman, MD, MSc
March 29, 2006
Covering:
Kappelhoff BS et al., HIV Clin Trials 2005 Sep/Oct; 6:254-61
